Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation.
- Author:
Shanti ESWARAN
1
;
Amanda GUENTNER
;
William D CHEY
Author Information
1. University of Michigan Health System, Ann Arbor, MI, USA. wchey@umich.edu
- Publication Type:Review
- Keywords:
Bile acid and salts;
Constipation;
Irritable bowel syndrome;
Laxatives;
Therapeutics
- MeSH:
Bile;
Constipation*;
Health Care Costs;
Irritable Bowel Syndrome*;
Laxatives;
Population Characteristics;
Quality of Life;
Serotonin Receptor Agonists;
Lubiprostone
- From:Journal of Neurogastroenterology and Motility
2014;20(2):141-151
- CountryRepublic of Korea
- Language:English
-
Abstract:
Irritable bowel syndrome with constipation and chronic functional constipation are common digestive disorders that negatively impact quality of life and account for billions of dollars in health care costs. Related to the heterogeneity of pathogenesis that underlie these disorders and the failure of symptoms to reliably predict underlying pathophysiology, traditional therapies provide relief to only a subset of affected individuals. The evidence surrounding new and emerging pharmacologic treatments, which include both luminally and systemically acting drugs, is discussed here. These include agents such as lubiprostone, bile acid modulations, guanylate cyclase-C receptor agonists, serotonin receptor modulators and herbal therapies.
